Member Info for AquaeSulis01

Shychap yes your statement is correct but it was always recognised that matrixyl would take years not months to be phased out of brands, that a new faster, smarter, more powerful generation of matrixyl has been developed, and all this seeks to demonstrate is the possibility that it is down to the addition of zenakine, raised by thecontender, is possible. I n other words, besides having a number of unique properties zenakine is extremely versatile and can be used in isolation as the sole active, as demonstrated by the Scandia Cosmetics Morpheus range or combined with other Actives to enhance their performance.

That is also an excellent analogy Clio. BMW kept the Mini name as it was a well known and popular brand through design innovations that enhanced the driving experience whilst maintaining the classic iconic features. Putting zenakine into an established brand like matrixyl 3000 would refresh that product whilst providing a quicker route to a mass market for zenakine

How Zenakine™ works

A postbiotic driven, indirect collagen support pathway

Zenakine (Lactobacillus ferment lysate) stimulates collagen I and III, but through cellular environment optimisation, not matrikine mimicry.

Its mechanisms include:

• reducing inflammatory cytokines

• improving fibroblast metabolic efficiency

• enhancing mitochondrial activity

• improving barrier signalling

• modulating microbiome linked repair pathways

This leads to increased collagen, but the signal is:

• indirect

• broader

• less receptor specific

• not tied to the GHK/matrikine pathway

Zenakine improves the conditions under which fibroblasts produce collagen, rather than directly commanding them to do so.

Why direct collagen I/III/IV/VII stimulation is lost when Tripeptide 1 is removed

Even though Zenakine increases collagen I and III, it does not:

• bind the same receptors

• activate the same matrikine pathways

• trigger the same gene expression cascade

• stimulate collagen IV or VII

• upregulate fibronectin or HA in the same way

• mimic collagen fragments

Tripeptide 1 is a precision tool. Zenakine is a system wide optimiser.

Removing Tripeptide 1 removes the matrikine specific anabolic signal, which is the only cosmetic pathway that directly mimics collagen breakdown fragments

Putting it together

When Tripeptide 1 is present

You get:

• direct collagen I/III/IV/VII synthesis

• strong wrinkle reduction kinetics

• a classic Matrixyl type anabolic response

When Tripeptide 1 is removed and Zenakine is used instead

You get:

• collagen I/III stimulation, but indirectly

• improved repair environment

• reduced inflammation

• better resilience

• slower, less intense collagen building

The system becomes postbiotic centric, not matrikine centric.

The key insight

Zenakine can support collagen production. Tripeptide 1 can command collagen production.

That is why replacing Tripeptide 1 with Zenakine changes the fundamental behaviour of the system, even though both increase collagen I and III.

Strategic interpretation

Adding Zenakine enhances Matrixyl 3000. Replacing Tripeptide 1 with Zenakine changes the identity of the system.

• Addition = augmentation

• Replacement = repositioning

The first scenario creates a next generation peptide plus postbiotic complex. The second creates a microbiome centric anti inflammatory repair system that no longer behaves like Matrixyl 3000.

So whilst Zenakine™ does stimulate collagen I and III, it does so through indirect, microbiome mediated signalling, not through the direct matrikine pathway that Palmitoyl Tripeptide 1 activates. That distinction is the reason the two ingredients are not interchangeable, even though both ultimately increase collagen.

The difference lies in how they signal fibroblasts, which receptors they activate, and what downstream genes they influence.

A direct matrikine collagen synthesis signal

Palmitoyl Tripeptide 1 is a synthetic fragment of collagen type I. When fibroblasts detect it, they interpret it as a sign of collagen breakdown and respond by directly upregulating:

• collagen I

• collagen III

• collagen IV

• collagen VII

• fibronectin

• hyaluronic acid

This is a receptor specific, high intensity anabolic signal. It is one of the most direct collagen building pathways in cosmetic science.

This is why Matrixyl 3000 produces strong wrinkle reduction data: Tripeptide 1 is a collagen production accelerator.

Scenario 2: Replacing Palmitoyl Tripeptide 1 with Zenakine

(Pal Tetrapeptide 7 + Zenakine)

This scenario removes the primary collagen stimulating peptide from Matrixyl 3000. Tripeptide 1 is the peptide that mimics the GHK fragment of collagen and directly triggers fibroblasts to synthesise new matrix proteins.

What is lost

• Direct collagen I/III/IV/VII stimulation

• Fibronectin and hyaluronic acid upregulation

• The classic matrikine feedback loop that “tricks” the skin into producing more collagen

Without Tripeptide 1, the system loses its strongest anabolic driver.

What remains

• Tetrapeptide 7’s anti inflammatory protection

• Zenakine’s postbiotic driven fibroblast activation and repair signalling

Zenakine can stimulate collagen indirectly through improved cellular metabolism and reduced inflammation, but it does not replicate the precise GHK type signalling of Tripeptide 1.

Expected performance shift

• Collagen synthesis: Moderate (Zenakine driven), but lower than Matrixyl 3000’s dual peptide synergy

• Inflammation control: Strong (Tetrapeptide 7 + Zenakine)

• Barrier repair: Strong

• Wrinkle reduction: Good, but not as fast or pronounced as the full Matrixyl 3000 system

• Skin resilience: Improved due to microbiome linked pathways

What this creates

A postbiotic centric repair system with anti inflammatory support, but without the high intensity collagen building signature of Matrixyl 3000

Agree Toyin. Final thoughts on how Croda will stay ahead of competitors with a zenakine enhanced version of Matrixyl 3000 with "nout taken out"

The Final Piece in the Jigsaw - Matrixyl 3000 Plus

So asking the questions from an active ingredient perspective this could be what we can expect to see if it is zenakine added to both Actives, palmitoyl tripeptide 1 and palmitoyl tetrapeptide 7 in the upcoming Croda release and how it outperforms both the current Matrixyl 3000 formula or a competitors formula using just palmitoyl tetrapeptide 7 plus zenakine:

Scenario 1: Adding Zenakine™ to the existing Matrixyl 3000 formula

(Pal Tripeptide 1 + Pal Tetrapeptide 7 + Zenakine)

Matrixyl 3000 already combines two complementary mechanisms:

• Palmitoyl Tripeptide 1 stimulates collagen I/III/IV/VII synthesis via TGF β signalling.

• Palmitoyl Tetrapeptide 7 reduces IL 6 and other inflammatory cytokines, slowing matrix degradation.

Zenakine (a Lactobacillus ferment lysate) introduces a third axis of activity: microbiome mediated cytokine modulation and fibroblast activation.

Expected combined effects

• Amplified collagen production because fibroblasts receive both GHK type stimulation (Tripeptide 1) and postbiotic driven metabolic activation.

• Stronger anti inflammatory environment as Tetrapeptide 7 and Zenakine both suppress inflammatory cytokines, but through different pathways.

• Improved repair signalling because postbiotics enhance cell–cell communication and barrier recovery.

• Better resilience under stress (UV, pollution, glycation), as Zenakine type lysates often upregulate antioxidant and repair genes.

What this creates

A triple mechanism anti ageing system:

1. Build collagen (Tripeptide 1)

2. Protect collagen (Tetrapeptide 7)

3. Optimise the repair environment (Zenakine)

This is the most potent scenario because nothing is removed—only layered.

One important but intriguing correction, even though the patents appeared on a Sederma search they are actually Mary Kay patents however, the narrative does tie in with zenakine.

Zenakine™ (a Lactobacillus ferment lysate) is positioned in Croda’s materials as a cytokine‑modulating, fibroblast‑activating postbiotic. Its documented effects include:

stimulation of collagen I and III synthesis

reduction of inflammatory cytokines

acceleration of repair pathways

modulation of extracellular matrix turnover

These are the same biological endpoints historically associated with Palmitoyl Tripeptide‑1, the collagen‑stimulating half of Matrixyl 3000.

If Mary Kay (or any brand in this patent family) adopts Zenakine™ as a core active, the need for Palmitoyl Tripeptide‑1 disappears (The actives in Matrixyl 3000 are Palmitoyl Tripeptide-1 (and) Palmitoyl Tetrapeptide-7 (old name Tetrapeptide-3))and indeed is not mentioned in the latest patent application)

Previous version of the Patent

Previous US Patent Application US-12515080-B2 Publication date 06/01/26

Narrative is built around:

• a simpler botanical + ferment + humectant blend

• no synergy claims

• no peptide technology

• no circadian rhythm positioning

The abstract and early sections do not include these detailed vehicle constraints. The focus is on the actives, not the vehicle architecture.

Lists dozens of optional actives (pumpkin seed extract, camu camu, ferula root, Alteromonas ferment, etc.) and multiple synergistic combinations.

The sleep mode narrative is absent. The claims are simplified to:

• “A method of treating skin… topically applying… a composition that includes [list of extracts].”

All peptide language is removed. There is no mention of:

• palmitoyl tetrapeptide 7

• palmitoyl tetrapeptide 3

• Matrixyl

• Matrixyl 3000

• methylsilanol mannuronate

This is a major substantive change

The core actives are different. The abstract and claims pivot to:

• Castanea sativa seed extract

• Lactobacillus ferment

• Punica granatum extract

• Camellia sinensis leaf extract

• niacinamide

• sodium hyaluronate

• glycerin

• butylene glycol

“The method includes topically applying… a composition that includes Castanea sativa seed extract, Lactobacillus ferment, Punica granatum extract, Camellia sinensis leaf extract, niacinamide, sodium hyaluronate, glycerin, and butylene glycol.”

Implication

The earlier patent covers a different formulation than the one described in the later application. The peptide centric, sleep mode synergy narrative disappears entirely in the earlier version.

Further to the zenakine in Matrixyl 3000 speculation, there was a significant update to a Sederma US Patent yesterday which adds wait to this theory

https://ppubs.uspto.gov/basic/ and put Sederma in the search.

Comparison follows

Latest Sederma US Patent Application US-20260083651-A1Publication date 26/03/26

Structural difference in the invention narrative

Narrative is built around:

• synergy

• chemical compatibility

• sleep mode physiology

• multi extract botanical synergy

• peptide + ferment + plant extract triad

Contains extensive formulation detail:

• water:glycerin ratios

• hydrating vehicles

• viscosity ranges

• optional exclusion of sunscreen agents, vitamins, oils

• multiple embodiments with different vehicles

Strong emphasis on evening / sleep mode skin repair:

• “treating skin during sleep”

• “works surprisingly well in treating skin during the evening hours”

• “recover/recuperate during sleep mode”

Contains extensive discussion of:

• palmitoyl tetrapeptide 7

• palmitoyl tetrapeptide 3

• methylsilanol mannuronate

• commercial sources such as Matrixyl 3000™ (Sederma)

“Palmitoyl tetrapeptide 3… can be purchased… under the trade names EYELISS™, HALOXYL™, MATRIXYL 3000™, and RIGIN™.”

The invention is framed around a specific “unique combination” of actives:

• palmitoyl tetrapeptide 7

• methylsilanol mannuronate

• Lactobacillus ferment

• plant extracts from:

o Punica granatum

o Castanea sativa

o Gossypium hirsutum

o Euterpe oleracea

This combination is repeatedly emphasised as the central inventive concept, especially for evening/sleep mode skin repair.

“the composition includes a combination of palmitoyl tetrapeptide 7, methylsilanol mannuronate, Lactobacillus ferment, and plant extracts from Punica granatum, Castanea sativa, Gossypium hirsutum, and Euterpe oleracea…”

Hughie Green Gardie :)

You've got the wrong old show net; it's more Opportunity Knocks and i mean that most sincerely folks

Think there is a strong chance they will combine zenakine with matrixyl. Had ignored the NAD+ increase of 60.51% (see slide 21 at the link)

NAD+ is a key intracellular coenzyme involved in

cell longevity. It acts as an electron donnor that

modulates cell redox state and fuels OXPHOS

for energy (ATP) production.

Zenakine promotes NAD+/NADH

mitochondrial ratio and boosts energy

production in keratinocytes, necessary for

cell renewal and metabolism.

https://www.skinbiotherapeutics.com/wp-content/uploads/2025/04/Croda-Beauty-Actives_Technical-seminar-theatre-4_8th.pdf

What has brought it into focus is the importance the Koreans place on increasing NAD+ with their current ingredient mixed with Matrixyl 3000 which only increases NAD+ by 10%

Scroll down to Cos De BAHA 10% NAD+ & Matrixyl 3000 & EGF & FGF Serum at the link

https://www.koreanskincarecoach.com/blog/top-skincare-trends-for-2026-and-the-ingredients-driving-the-shift

Speaker on Sun Care at In-cosmetics 2026

https://www.in-cosmetics.com/global/en-gb/show-programme/sessions-details.4740.255596.powering-up-protection-redefining-high-performance-sun-care.html

Co-Pilot assisted Analysis:

2. Croda’s launch pattern is tiered, not binary

Croda does not operate on a simple “not launched / launched” model.

They use a tiered activation strategy, especially for new biotech actives.

Here’s the actual pattern:

Phase 1 — Scientific Reveal

✔ Already happened (last year)

Phase 2 — Catalogue Inclusion

✔ Already happened (Zenakine™ now listed)

Phase 3 — Selective Early Commercial Supply

✔ This is where Scandia Cosmetic fits

Croda often allows:

• regional brands

• smaller brands

• early adopters

• low risk markets

…to launch before the global marketing push.

Phase 4 — Global Commercial Activation

⚠ Not yet complete

This includes:

• hero formulations

• distributor activation

• distributor concept formulations

• global marketing pack

• coordinated in cosmetics showcase

Phase 5 — Widespread Brand Adoption

❌ Not yet happening

(no major global brands using Zenakine™ publicly)

So Scandia Cosmetic’s Morpheus range is a Phase 3 early adopter, not evidence of Phase 4 completion.

Competitive timing reinforces the likelihood

2026 is shaping up to be a biotech heavy in cosmetics year.

Croda will not want to:

• lose narrative ground to Givaudan Active Beauty

• let Ashland or DSM Firmenich dominate the “skin resilience” story

• allow Evonik to own the “post stress recovery” space

Zenakine™ is Croda’s strongest biotech narrative in years.

They need a 2026 activation.

6. Structural conclusion

Zenakine™ now has:

• regulatory clearance

• catalogue inclusion

• early commercial validation

• a clear mechanistic story

• a Croda aligned positioning (barrier, inflammation, resilience)

• a natural activation window (Paris 2026)

Structurally, everything is aligned for Phase 4 at in cosmetics 2026.

Phase 4 is Croda’s full commercial activation.

It has three pillars:

1. Hero formulations

2. Distributor activation

3. Brand adoption

Hero formulation possibilities; A biotech forward minimalist serum, A barrier repair + comfort emulsion and A resilience boosting gel cream

Fingers crossed for April 14th-16th

In Serbian, “samo u Lilly” translates to:

“only in Lilly”

“Lilly” refers to Lilly Drogerie — a major Serbian retail chain that sells:

- cosmetics

- skincare

- personal care

- pharmacy‑adjacent OTC items

- household products

Think of it as the Serbian equivalent of Boots, DM, or Superdrug.

So when VZK Laboratory writes “samo u Lilly”, they are saying:

“This product is available exclusively at Lilly Drogerie stores.”

shychap posted the link revealing VZK was selling zenakine based products a while back

Lol, just my fingers doing the hard miles online :)

Axisbiotix-Ac

STOCK POS 20/12/25 24/01/26 18/02/26 20/03/26

IN-STOCK 27 42 42 39

LOW STOCK 73 62 117 131

NO STOCK 80 76 21 10

Axisbiotix-Ps

STOCK POS 05/01/26 02/02/26 26/02/26 20/03/26

IN-STOCK 38 39 41 43

LOW STOCK 93 87 118 123

NO STOCK 79 54 21 14

A steadily improving stock situation and by no means static. Axis-ps unsurprisingly appears the most active with 6 Stores changed from Low Stock to No Stock, 1 Store from In Stock to No Stock, 12 Stores from No Stock to Low Stock and 2 from No Stock to In Stock.

Axis-Ac shows 1 Store moved from In Stock to No Stock and 7 Stores moved from In Stock to Low Stock.

Some Stores have never held stock of either Axis-Ps or Axis-Ac; notably those in Northern Ireland but in contrast I came across Stores not on the Phase 1 roll out list that hold stock of both products

Ok, so you expect Royalties from Croda to be accrued before end June this year and the two acquired Businesses, which we are told are operating at cash break-even rather than contributing profits to the Group, to generate sufficient revenue to get near the £6.2M forecast?

Toyin, the Singer's forecast of £6.2M included Croda Royalties "We assume an uplift in FY26E gross profit margin to 63.9%, reflecting an improved sales mix, and Croda royalties which drop through to thebottom line, with gross profit therefore expected to be £4.0m"

You're asking the wrong question net, the who is easy enough to identify, it is what brought zenakine to her attention and where did she obtain the product to try? Regarding the who, I doubt very much any of her followers will be looking closely at her face to see whether she has fewer wrinkles.

https://www.facebook.com/people/AiraOfficial/61585198148458/